Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.54 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.50 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.50 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.48 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716308 | 0.89 | MEP1B (0.59) | SLC2A1NR1H3MEP1BMEP1ASLC2A4 | |
| SCHEMBL1035892 | 0.87 | SLC2A1 (0.49) | SLC2A1SLC2A4SLC2A8ACHE | |
| SCHEMBL1034160 | 0.84 | SLC2A1 (0.47) | SLC2A1NR1H3SLC2A4SLC2A8TAS2R14 | |
| SCHEMBL1037725 | 0.84 | NR1H3 (0.49) | SLC2A1NR1H3SLC2A4SLC2A8TAS2R14 | |
| SCHEMBL1039110 | 0.78 | SIGMAR1 (0.51) | MEP1BACHE | |
| SCHEMBL11413988 | 0.77 | THRA (0.59) | MEP1B | |
| SCHEMBL1037264 | 0.76 | SLC2A1 (0.47) | SLC2A1ACHE | |
| SCHEMBL2062287 | 0.75 | CALM1 (0.62) | NR1H3MEP1BMEP1ATAS2R14PPARG | |
| SCHEMBL1036749 | 0.75 | KDM4E (0.48) | MEP1BRAB9AACHE | |
| SCHEMBL1033735 | 0.75 | KDM4E (0.44) | SLC2A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831173-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-26 | — | — | EP | disclosed |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | HRH3, HRH4, HRH1 | SLC2A1 376/4885NR1H3 116/4885MEP1B 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.